Driehaus Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Driehaus Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-107,053	Closed	-$4.11M	–	465
2023 Q2	$4.11M	Sell	107,053 -648,283	-86%	-$16.6M	0.05%	280
2023 Q1	$17.5M	Sell	755,336 -17,364	-2%	-$414K	0.25%	139
2022 Q4	$20.2M	Sell	772,700 -108,984	-12%	-$2.41M	0.3%	109
2022 Q3	$17.3M	Buy	881,684 +389,381	+79%	+$7.81M	0.26%	117
2022 Q2	$8.61M	Buy	+492,303	New	+$7.73M	0.14%	217

Driehaus Capital Management's KDNY Position: Q3 2023 in Review

Driehaus Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 107,053 shares — an estimated $4.11M sold.

Driehaus Capital Management first reported a position in KDNY in Q2 2022 and held it in 5 quarters. The position peaked at $20.2M in Q4 2022. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Driehaus Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Driehaus Capital Management sold 107,053 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $4.11M.
Driehaus Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2022 and held it in 5 quarters.
Driehaus Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $20.2M in Q4 2022.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Driehaus Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.